PL3679034T3 - Pochodne 1-(4-(izoksazol-5-ilo)-1h-pirazol-1-ilo)-2-metylo-propan-2-olu i związki pokrewne jako inhibitory il-7 i ifn-gamma do leczenia chorób autoimmunologicznych i przewlekłego zapalenia - Google Patents

Pochodne 1-(4-(izoksazol-5-ilo)-1h-pirazol-1-ilo)-2-metylo-propan-2-olu i związki pokrewne jako inhibitory il-7 i ifn-gamma do leczenia chorób autoimmunologicznych i przewlekłego zapalenia

Info

Publication number: PL3679034T3
Authority: PL; Poland
Prior art keywords: ilo; isoxazol; propan; ifn; pyrazole
Prior art date: 2017-09-06

Application number

PL18762111.5T

Other languages

English (en)

Inventor

Jakob Felding

Hella KOHLHOF

Manfred GRÖPPEL

Rolf Andreas MÜHLER

Daniel Vitt

Carine Chevrier

Mirko Zaja

Stefan Tasler

Original Assignee

Immunic Ag

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2017-09-06

Filing date

2018-09-06

Publication date

2022-11-14

2018-09-06 Application filed by Immunic Ag filed Critical Immunic Ag

2022-11-14 Publication of PL3679034T3 publication Critical patent/PL3679034T3/pl

Links

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/415—1,2-Diazoles
- A61K31/4155—1,2-Diazoles non condensed and containing further heterocyclic rings
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/42—Oxazoles
- A61K31/422—Oxazoles not condensed and containing further heterocyclic rings
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4965—Non-condensed pyrazines
- A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
- A61K31/541—Non-condensed thiazines containing further heterocyclic rings
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/10—Spiro-condensed systems
- C07D491/107—Spiro-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Medicinal Chemistry (AREA)
Animal Behavior & Ethology (AREA)
Life Sciences & Earth Sciences (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
General Health & Medical Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Chemical Kinetics & Catalysis (AREA)
Epidemiology (AREA)
Immunology (AREA)
Diabetes (AREA)
Dermatology (AREA)
Urology & Nephrology (AREA)
Cardiology (AREA)
Rheumatology (AREA)
Physical Education & Sports Medicine (AREA)
Vascular Medicine (AREA)
Heart & Thoracic Surgery (AREA)
Orthopedic Medicine & Surgery (AREA)
Endocrinology (AREA)
Hematology (AREA)
Obesity (AREA)
Transplantation (AREA)
Emergency Medicine (AREA)
Child & Adolescent Psychology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Plural Heterocyclic Compounds (AREA)
Nitrogen Condensed Heterocyclic Rings (AREA)

PL18762111.5T 2017-09-06 2018-09-06 Pochodne 1-(4-(izoksazol-5-ilo)-1h-pirazol-1-ilo)-2-metylo-propan-2-olu i związki pokrewne jako inhibitory il-7 i ifn-gamma do leczenia chorób autoimmunologicznych i przewlekłego zapalenia PL3679034T3 (pl)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
EP17189652		2017-09-06
PCT/EP2018/073993 WO2019048541A1 (en)	2017-09-06	2018-09-06	1- (4- (ISOXAZOL-5-YL) -1H-PYRAZOL-1-YL) -2-METHYLPROPAN-2-OL DERIVATIVES AND RELATED COMPOUNDS AS INHIBITORS OF IL-17 AND IFN- GAMMA FOR THE TREATMENT OF AUTOIMMUNE DISEASES AND CHRONIC INFLAMMATION

Publications (1)

Publication Number	Publication Date
PL3679034T3 true PL3679034T3 (pl)	2022-11-14

Family

ID=59799324

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
PL18762111.5T PL3679034T3 (pl)	2017-09-06	2018-09-06	Pochodne 1-(4-(izoksazol-5-ilo)-1h-pirazol-1-ilo)-2-metylo-propan-2-olu i związki pokrewne jako inhibitory il-7 i ifn-gamma do leczenia chorób autoimmunologicznych i przewlekłego zapalenia

Country Status (27)

Country	Link
US (1)	US11292788B2 (pl)
EP (2)	EP4074708A1 (pl)
JP (2)	JP2020532575A (pl)
KR (1)	KR20200069299A (pl)
CN (1)	CN111433202A (pl)
AU (1)	AU2018330633C1 (pl)
CA (1)	CA3074891A1 (pl)
CY (1)	CY1125514T1 (pl)
DK (1)	DK3679034T3 (pl)
ES (1)	ES2925538T3 (pl)
HR (1)	HRP20221042T1 (pl)
HU (1)	HUE059822T2 (pl)
IL (1)	IL273064B2 (pl)
LT (1)	LT3679034T (pl)
MA (1)	MA50069B1 (pl)
MD (1)	MD3679034T2 (pl)
MX (1)	MX2020002571A (pl)
PH (1)	PH12020500461A1 (pl)
PL (1)	PL3679034T3 (pl)
PT (1)	PT3679034T (pl)
RS (1)	RS63532B1 (pl)
SG (1)	SG11202001409UA (pl)
SI (1)	SI3679034T1 (pl)
SM (1)	SMT202200343T1 (pl)
UA (1)	UA126689C2 (pl)
WO (1)	WO2019048541A1 (pl)
ZA (1)	ZA202001179B (pl)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
JP2020532575A (ja) *	2017-09-06	2020-11-12	イミュニックアクチェンゲゼルシャフト	自己免疫疾患及び慢性炎症を治療するためのｉｌ−１７及びｉｆｎ−ガンマの阻害剤としての１−（４−（イソオキサゾール−５−イル）−１ｈ−ピラゾール−１−イル）−２−メチルプロパン−２−オール誘導体及び関連化合物
WO2023281097A1 (en)	2021-07-09	2023-01-12	Immunic Ag	Methods for treating cancer
CN113683505A (zh) *	2021-09-29	2021-11-23	厦门大华本安化工安全研究院有限公司	一种含氧代环丁基的羧酸酯类化合物的制备方法
US20250243190A1 (en)	2022-04-14	2025-07-31	Immunic Ag	New deuterated rorgamma/rorgammat inverse agonists
WO2023232870A1 (en)	2022-05-31	2023-12-07	Immunic Ag	Rorg/rorgt modulators for the treatment of virus infections like covid-19
CN119192167B (zh) *	2024-11-28	2025-03-21	英矽智能科技(上海)有限公司	一类抑制il-17的化合物

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
ES2664219T3 (es) *	2011-01-28	2018-04-18	Immunic Ag	Inhibición de IL17 e IFN-gamma para el tratamiento de una inflamación autoinmunitaria
JP5969505B2 (ja)	2011-01-28	2016-08-17	４エスツェーディスカバリーゲゼルシャフトミットベシュレンクテルハフツング	自己免疫性炎症の治療のためのＩＬ１７及びＩＦＮ−γ阻害
JP2020532575A (ja) *	2017-09-06	2020-11-12	イミュニックアクチェンゲゼルシャフト	自己免疫疾患及び慢性炎症を治療するためのｉｌ−１７及びｉｆｎ−ガンマの阻害剤としての１−（４−（イソオキサゾール−５−イル）−１ｈ−ピラゾール−１−イル）−２−メチルプロパン−２−オール誘導体及び関連化合物

2018
- 2018-09-06 JP JP2020514532A patent/JP2020532575A/ja active Pending
- 2018-09-06 CA CA3074891A patent/CA3074891A1/en active Pending
- 2018-09-06 MA MA50069A patent/MA50069B1/fr unknown
- 2018-09-06 KR KR1020207009871A patent/KR20200069299A/ko not_active Ceased
- 2018-09-06 PL PL18762111.5T patent/PL3679034T3/pl unknown
- 2018-09-06 CN CN201880058056.9A patent/CN111433202A/zh active Pending
- 2018-09-06 SG SG11202001409UA patent/SG11202001409UA/en unknown
- 2018-09-06 LT LTEPPCT/EP2018/073993T patent/LT3679034T/lt unknown
- 2018-09-06 MX MX2020002571A patent/MX2020002571A/es unknown
- 2018-09-06 UA UAA202002206A patent/UA126689C2/uk unknown
- 2018-09-06 SM SM20220343T patent/SMT202200343T1/it unknown
- 2018-09-06 DK DK18762111.5T patent/DK3679034T3/da active
- 2018-09-06 MD MDE20200707T patent/MD3679034T2/ro unknown
- 2018-09-06 HR HRP20221042TT patent/HRP20221042T1/hr unknown
- 2018-09-06 PT PT187621115T patent/PT3679034T/pt unknown
- 2018-09-06 AU AU2018330633A patent/AU2018330633C1/en not_active Ceased
- 2018-09-06 SI SI201830741T patent/SI3679034T1/sl unknown
- 2018-09-06 EP EP22176185.1A patent/EP4074708A1/en not_active Withdrawn
- 2018-09-06 US US16/644,581 patent/US11292788B2/en active Active
- 2018-09-06 WO PCT/EP2018/073993 patent/WO2019048541A1/en not_active Ceased
- 2018-09-06 ES ES18762111T patent/ES2925538T3/es active Active
- 2018-09-06 HU HUE18762111A patent/HUE059822T2/hu unknown
- 2018-09-06 RS RS20220796A patent/RS63532B1/sr unknown
- 2018-09-06 EP EP18762111.5A patent/EP3679034B1/en active Active
2020
- 2020-02-25 ZA ZA2020/01179A patent/ZA202001179B/en unknown
- 2020-03-04 IL IL273064A patent/IL273064B2/en unknown
- 2020-03-06 PH PH12020500461A patent/PH12020500461A1/en unknown
2022
- 2022-08-25 CY CY20221100574T patent/CY1125514T1/el unknown
- 2022-12-23 JP JP2022206807A patent/JP2023052060A/ja active Pending

Also Published As

Publication number	Publication date
MX2020002571A (es)	2020-10-01
ZA202001179B (en)	2023-03-29
EP4074708A1 (en)	2022-10-19
BR112020004332A2 (pt)	2020-09-08
US11292788B2 (en)	2022-04-05
RU2020112319A (ru)	2021-10-06
SI3679034T1 (sl)	2022-11-30
JP2023052060A (ja)	2023-04-11
AU2018330633A1 (en)	2020-03-05
AU2018330633B2 (en)	2021-02-25
WO2019048541A1 (en)	2019-03-14
US20210061796A1 (en)	2021-03-04
AU2018330633C1 (en)	2022-02-24
LT3679034T (lt)	2022-09-12
RU2020112319A3 (pl)	2022-02-07
IL273064B2 (en)	2023-06-01
PH12020500461A1 (en)	2021-01-11
CN111433202A (zh)	2020-07-17
PT3679034T (pt)	2022-08-29
HUE059822T2 (hu)	2022-12-28
MA50069A (fr)	2021-05-05
NZ761897A (en)	2023-10-27
JP2020532575A (ja)	2020-11-12
SMT202200343T1 (it)	2022-11-18
KR20200069299A (ko)	2020-06-16
CY1125514T1 (el)	2026-02-25
DK3679034T3 (da)	2022-08-29
MA50069B1 (fr)	2023-08-31
EP3679034A1 (en)	2020-07-15
IL273064A (en)	2020-04-30
MD3679034T2 (ro)	2022-10-31
ES2925538T3 (es)	2022-10-18
UA126689C2 (uk)	2023-01-11
HRP20221042T1 (hr)	2022-11-11
CA3074891A1 (en)	2019-03-14
EP3679034B1 (en)	2022-06-01
RS63532B1 (sr)	2022-09-30
SG11202001409UA (en)	2020-03-30

Publication	Publication Date	Title
IL289534A (en)	2022-03-01	Parp1 inhibitors
IL282487A (en)	2021-06-30	Tyk2 inhibitors and uses thereof
PL3710439T3 (pl)	2023-06-26	Inhibitory kras g12c
PL3679034T3 (pl)	2022-11-14	Pochodne 1-(4-(izoksazol-5-ilo)-1h-pirazol-1-ilo)-2-metylo-propan-2-olu i związki pokrewne jako inhibitory il-7 i ifn-gamma do leczenia chorób autoimmunologicznych i przewlekłego zapalenia
IL256056A (en)	2018-01-31	Ezh2 inhibitors for treating lymphoma
IL261721A (en)	2018-10-31	Combinations of lsd1 inhibitors for use in the treatment of solid tumors
PL3472153T3 (pl)	2022-02-07	Pirymidyn-2-yloamino-1h-pirazole jako inhibitory lrrk2 do zastosowania w leczeniu zaburzeń neurodegeneracyjnych
IL275948A (en)	2020-08-31	History of H2-indazole as CDK4 and CDK6 inhibitors and their medical uses
IL247841A0 (en)	2016-11-30	Heterocyclic compounds for use in the treatment of pi3k-gamma mediated disorders
EP3432927A4 (en)	2019-11-20	TRIPLE-SPECIFIC INHIBITORS FOR CANCER TREATMENT
IL249895A0 (en)	2017-03-30	2-h-indazole derivatives as cyclin-dependent kinase (cdk) inhibitors and therapeutic uses thereof
LT3768674T (lt)	2024-04-25	Aminopirimidino dariniai kaip ctps1 inhibitoriai
PL3157534T3 (pl)	2022-09-12	Inhibitory acetylocholinesteraz w leczeniu stanów dermatologicznych
EP3256218A4 (en)	2018-08-08	Kdm1a inhibitors for the treatment of disease
EA201591509A1 (ru)	2015-12-30	Ингибиторы cdc7
PL3539961T3 (pl)	2022-02-14	Policykliczne pochodne amidowe jako inhibitory CDK9
EP3174539A4 (en)	2017-12-13	Inhibitors of bruton's tyrosine kinase
IL279260A (en)	2021-01-31	KDM1A inhibitors for the treatment of diseases
PL3485890T3 (pl)	2023-08-28	Inhibitory SGLT2 do leczenia zaburzeń metabolicznych u zwierząt psowatych
EP3206749A4 (en)	2018-06-20	Use of cdk9 and brd4 inhibitors to inhibit inflammation
IL283069A (en)	2021-06-30	Methods for administering corticosteroids
EA201790484A1 (ru)	2017-10-31	Производные тетрагидрохинолина в качестве ингибиторов бромодомена
IL263804A (en)	2019-01-31	Wnt inhibitors for use in the treatment of fibrosis
PL3373922T3 (pl)	2022-05-02	Kompozycje i sposoby do stosowania do leczenia homocystynurii
PL3697399T3 (pl)	2026-03-23	Środki terapeutyczne do zastosowania w leczeniu zespołu niespokojnych nóg